Our Services
Medical Information
Helpful Resources
Published on: 5/5/2026
Your doctor prevents nausea during a fast NAD+ IV drip by ensuring you are well hydrated and lightly fed before treatment and may pre-medicate with antiemetics like ondansetron or diphenhydramine.
Infusions are started slowly with properly warmed, diluted, and pH balanced saline while monitoring vital signs and symptoms.
There are several factors to consider, including individual sensitivities and medical history; see complete details below to guide your next healthcare steps.
NAD+ IV therapy can offer benefits like improved energy, mental clarity, and cellular repair. However, rapid infusion of NAD+ (nicotinamide adenine dinucleotide) may sometimes cause nausea. Here's a comprehensive guide on NAD+ IV nausea prevention, based on credible clinical practice and expert insights.
Your doctor will:
Adequate hydration before infusion helps stabilize vascular volume and reduce nausea risk.
Based on your history, preemptive meds may include:
Slower rates allow your body to adapt to osmolar changes and decrease vagal stimulation.
Vital Signs
Symptom Assessment
Immediate Interventions
While mild nausea is usually manageable, certain symptoms require immediate medical attention:
If you experience any of these, stop the infusion and seek medical care right away.
Not sure if your symptoms warrant medical attention? Use this free Medically approved LLM Symptom Checker Chat Bot to get instant, confidential guidance on whether you should consult a healthcare provider about your nausea or other concerning symptoms.
Above all, always speak to your doctor about any serious, persistent, or life-threatening concerns. Proper preparation and professional oversight can significantly reduce discomfort and help you maximize the benefits of NAD+ IV therapy.
(References)
* Dorr, H., Geyer, K. M., Farias, J., & Geyer, S. (2018). Safety and Efficacy of Intravenous Nicotinamide Adenine Dinucleotide (NAD+) for Addiction Treatment: A Retrospective Chart Review. *Journal of Addiction Research & Therapy*, *9*(3), 369.
* Fang, E. F., Kassahun, H., Croteau, D. L., Scheibye-Knudsen, M., Swenberg, J. A., Nilsen, H., & Bohr, V. A. (2019). Targeting NAD+ in aging and disease: Clinical challenges and opportunities. *Cell Metabolism*, *30*(6), 1017-1033.
* Minhas, F., Sun, H., Nguyen, H., Rahn, S. N., Rahn, S. M., Al-Ghalith, G., ... & Baur, J. A. (2021). Pharmacokinetics and Safety of a Stabilized Nicotinamide Adenine Dinucleotide (NAD+) Formulation in Humans: A Randomized, Double-Blind, Placebo-Controlled Study. *The Journal of Clinical Pharmacology*, *61*(12), 1640-1650.
* Lu, Z., Ma, S., Li, Y., Jiang, Y., Wang, P., Wei, Z., ... & Chen, X. (2023). Clinical application of intravenous nicotinamide adenine dinucleotide (NAD+) for Parkinson's disease: A systematic review. *Frontiers in Neurology*, *14*, 1243110.
* Broom, W., Sgorbati, R., & Sgorbati, S. (2020). Intravenous Nicotinamide Adenine Dinucleotide in the Treatment of Drug and Alcohol Withdrawal. *Journal of Behavioral Addictions*, *9*(3), 598-600.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.